Its also best to limit or eliminate alcohol and fried foods because these also contribute to inflammation
Prescribers initiating BPC-157 in patients with Child-Pugh A or B hepatic impairment should document: (1) the clinical rationale for peptide therapy, (2) the absence of an FDA-approved alternative for the target condition, (3) baseline hepatic function with planned monitoring intervals, and (4) the patient's informed consent acknowledging the investigational nature of the therapy and the specific evidence limitations in their population
We do see regularly see complications from cheek fillers done by untrained providers, mostly non physicians (nurses, physician assistants and dentists) who have a paucity of knowledge, training and experience
Medication alone is rarely sufficient for long-term success
Compounded semaglutide, prepared by licensed compounding pharmacies, can be a legally available alternative when prescribed by a healthcare provider
BPC-157 is a relatively small peptide (molecular weight approximately 1,419 Da), and its stability against proteolytic degradation has been noted in vitro, but whether it reaches the liver in sufficient concentration to affect CYP activity is unknown